Hospital
ST Bernards Hospital INC
ST Bernards Hospital INC was paid $35.44M by Medicaid between Jan 2018 and Dec 2024, across 492 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 5.8% of everything it billed.
33Billing provider infoST BERNARDS HOSPITAL INC
JONESBORO, AR 72401
JONESBORO, AR 72401
33aNPI1922043686assigned 06/18/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$35.44M
24GClaims1,543,934
24DCodes billed492
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Arkansas
Rank by total paid#2 of 49
Median peer was paid$2.62M
This provider vs. median14×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 190,972 | $4.05M | |
| 2019 | 201,654 | $5.60M | |
| 2020 | 165,562 | $4.69M | |
| 2021 | 175,198 | $4.97M | |
| 2022 | 255,590 | $5.14M | |
| 2023 | 298,447 | $5.79M | |
| 2024incomplete | 256,511 | $5.20M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.8% | 59,145 | 13,082 | $2.06M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 3.8% | 10,622 | 8,948 | $1.36M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.2% | 8,398 | 7,462 | $1.14M |
| 80053 | Comprehensive metabolic panel | 3.1% | 97,109 | 74,659 | $1.09M |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2.9% | 3,865 | 3,365 | $1.02M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 9,408 | 8,188 | $1.01M |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 2.5% | 2,935 | 2,444 | $896K |
| J9271 | Injection, pembrolizumab, 1 mg | 2.5% | 241 | 169 | $896K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 2.2% | 2,281 | 2,017 | $784K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 2.1% | 9,170 | 7,838 | $727K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.0% | 94,685 | 70,905 | $696K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 8,317 | 6,482 | $665K |
480 more codes
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.9% | 55,852 | $663K |
| T1015 | A visit at a community health center or clinic (one all-in rate) | 1.8% | 56,267 | $649K |
| J0897 | Injection, denosumab, 1 mg | 1.8% | 1,767 | $648K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 62,749 | $630K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.8% | 3,540 | $629K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.7% | 5,049 | $593K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.5% | 2,991 | $528K |
| 72141 | 1.4% | 2,016 | $510K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 1.3% | 3,930 | $469K |
| 72125 | Computed tomography, cervical spine; without contrast material | 1.3% | 3,521 | $461K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.3% | 13,504 | $457K |
| 99283 | Emergency room visit (moderate) | 1.2% | 9,947 | $412K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.2% | 1,955 | $410K |
| 83880 | 1.1% | 15,429 | $376K | |
| 97162 | <1% | 4,645 | $347K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,359 | $347K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 6,861 | $325K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,866 | $316K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,412 | $303K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,344 | $300K |
| 99284 | Emergency room visit (serious) | <1% | 9,370 | $283K |
| 80081 | <1% | 2,700 | $252K | |
| 84484 | <1% | 26,252 | $246K | |
| 71045 | Radiologic examination, chest; single view | <1% | 24,697 | $240K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 20,659 | $237K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 641 | $236K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 3,337 | $234K |
| 93351 | <1% | 1,320 | $231K | |
| 99285 | Emergency room visit (most serious) | <1% | 6,880 | $225K |
| 80061 | Lipid panel | <1% | 21,588 | $209K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 4,132 | $205K |
| 36415 | Collection of venous blood by venipuncture | <1% | 51,108 | $194K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 29,348 | $193K |
| 70486 | <1% | 1,465 | $191K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 11,135 | $188K |
| 93458 | <1% | 1,619 | $184K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,580 | $181K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 19,534 | $168K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,883 | $167K |
| 81001 | <1% | 42,043 | $164K | |
| 83735 | <1% | 25,586 | $162K | |
| 80050 | General health panel | <1% | 3,380 | $161K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 6,383 | $156K |
| 71250 | <1% | 1,813 | $148K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 6,756 | $142K |
| 97161 | <1% | 2,368 | $135K | |
| 83690 | <1% | 16,965 | $132K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,741 | $131K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 668 | $127K |
| 73221 | <1% | 546 | $125K | |
| 72131 | <1% | 1,058 | $121K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 4,339 | $121K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 5,414 | $115K |
| 85027 | <1% | 21,434 | $113K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 13,573 | $110K |
| 96367 | <1% | 2,325 | $109K | |
| H0018 | Behavioral health; short-term residential (non-hospital residential treatment program), without room and board, per diem | <1% | 284 | $109K |
| 76801 | <1% | 2,852 | $105K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 101 | $100K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 2,125 | $98K |
| 84703 | <1% | 8,648 | $96K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 2,748 | $94K |
| 93880 | <1% | 3,197 | $94K | |
| 80074 | <1% | 1,923 | $93K | |
| 93971 | <1% | 2,260 | $91K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,353 | $90K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 9,669 | $88K |
| 97001 | <1% | 2,195 | $88K | |
| 87428 | <1% | 1,304 | $86K | |
| 73562 | <1% | 2,988 | $84K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 6,652 | $81K |
| 87631 | <1% | 869 | $80K | |
| 80305 | <1% | 7,129 | $80K | |
| 70491 | <1% | 538 | $80K | |
| 73222 | <1% | 212 | $80K | |
| 70498 | <1% | 652 | $80K | |
| 74018 | <1% | 4,584 | $79K | |
| 82728 | <1% | 6,730 | $78K | |
| 87081 | <1% | 9,966 | $77K | |
| 87040 | <1% | 6,904 | $73K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,884 | $73K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 669 | $72K |
| 93976 | <1% | 1,190 | $72K | |
| 70496 | <1% | 572 | $72K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,480 | $72K |
| 93017 | <1% | 3,113 | $72K | |
| 73630 | <1% | 2,867 | $71K | |
| 76830 | Ultrasound, transvaginal | <1% | 1,157 | $70K |
| 86901 | <1% | 3,365 | $69K | |
| 87077 | <1% | 8,215 | $69K | |
| 82607 | <1% | 5,323 | $67K | |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 1,937 | $64K |
| 85730 | <1% | 14,212 | $63K | |
| 83605 | <1% | 5,658 | $63K | |
| 85610 | <1% | 20,956 | $62K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 6,838 | $58K |
| 76642 | <1% | 1,770 | $57K | |
| 84146 | <1% | 2,124 | $57K | |
| 72146 | <1% | 180 | $56K | |
| 93320 | <1% | 2,368 | $56K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,639 | $55K |
| 86703 | <1% | 3,073 | $54K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 221 | $53K |
| 73130 | <1% | 2,286 | $53K | |
| 95911 | <1% | 931 | $52K | |
| 82962 | <1% | 16,333 | $51K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 985 | $51K |
| 81025 | <1% | 5,647 | $50K | |
| C1769 | Guide wire | <1% | 2,186 | $50K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 236 | $49K |
| 87186 | <1% | 9,028 | $49K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,302 | $49K |
| 17110 | <1% | 419 | $48K | |
| 93970 | <1% | 1,813 | $47K | |
| 73030 | <1% | 2,657 | $47K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,096 | $46K |
| 36410 | <1% | 1,813 | $46K | |
| 51798 | <1% | 1,105 | $46K | |
| 93922 | <1% | 3,211 | $45K | |
| 77336 | <1% | 647 | $44K | |
| 76536 | <1% | 1,083 | $44K | |
| 84702 | <1% | 3,914 | $43K | |
| 73610 | <1% | 2,531 | $43K | |
| 84439 | <1% | 4,480 | $43K | |
| 76641 | <1% | 1,005 | $42K | |
| 76770 | <1% | 1,261 | $42K | |
| 95886 | <1% | 1,059 | $42K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 2,850 | $41K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 830 | $41K |
| 74178 | <1% | 357 | $41K | |
| 83615 | <1% | 6,698 | $40K | |
| 94726 | <1% | 1,525 | $40K | |
| 88342 | <1% | 1,929 | $39K | |
| 76937 | <1% | 3,917 | $39K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,236 | $39K |
| 87400 | <1% | 6,337 | $39K | |
| 86803 | <1% | 2,298 | $38K | |
| 77386 | <1% | 239 | $38K | |
| 47562 | <1% | 101 | $38K | |
| 83550 | <1% | 5,686 | $38K | |
| 86140 | <1% | 6,353 | $38K | |
| 82803 | <1% | 1,835 | $37K | |
| 93225 | <1% | 1,282 | $37K | |
| 82746 | <1% | 3,038 | $37K | |
| 80076 | <1% | 5,697 | $37K | |
| 77062 | <1% | 501 | $35K | |
| 72100 | <1% | 1,534 | $35K | |
| 83540 | <1% | 6,632 | $35K | |
| 82105 | <1% | 2,117 | $34K | |
| 73110 | <1% | 1,500 | $33K | |
| 88304 | <1% | 1,553 | $33K | |
| 88341 | <1% | 629 | $33K | |
| 36430 | <1% | 306 | $32K | |
| 84153 | <1% | 2,218 | $31K | |
| G0378 | Hospital observation service, per hour | <1% | 4,777 | $31K |
| 82565 | <1% | 6,512 | $31K | |
| 83516 | <1% | 1,936 | $30K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 430 | $30K |
| 23350 | <1% | 166 | $30K | |
| 87070 | <1% | 3,164 | $28K | |
| 73502 | <1% | 1,486 | $28K | |
| C8930 | Transthoracic echocardiography, with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, during rest and cardiovascular stress test using treadmill, bicycle exercise and/or pharmacologically induced stress, with interpretation and report; including performance of continuous electrocardiographic monitoring, with physician supervision | <1% | 327 | $27K |
| 93308 | <1% | 670 | $26K | |
| 72110 | <1% | 1,029 | $25K | |
| 12001 | <1% | 109 | $25K | |
| 86756 | <1% | 1,382 | $24K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 22 | $24K |
| 93325 | <1% | 2,577 | $23K | |
| 80164 | <1% | 1,842 | $22K | |
| 49083 | <1% | 105 | $22K | |
| 81003 | <1% | 7,663 | $21K | |
| 43235 | <1% | 122 | $20K | |
| 96417 | <1% | 348 | $20K | |
| 74183 | <1% | 47 | $20K | |
| 86038 | <1% | 1,632 | $18K | |
| 87205 | <1% | 3,944 | $18K | |
| 85379 | <1% | 1,619 | $18K | |
| 82550 | <1% | 2,486 | $18K | |
| 82570 | <1% | 3,415 | $18K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 171 | $17K |
| 77334 | <1% | 132 | $17K | |
| 94010 | <1% | 859 | $17K | |
| 82533 | <1% | 1,014 | $16K | |
| 73590 | <1% | 746 | $16K | |
| 74022 | <1% | 507 | $16K | |
| 86592 | <1% | 3,050 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 126 | $16K |
| 82677 | <1% | 461 | $15K | |
| 95811 | <1% | 132 | $15K | |
| 84436 | <1% | 2,173 | $15K | |
| 81002 | <1% | 4,252 | $15K | |
| 73560 | <1% | 1,008 | $14K | |
| 82950 | <1% | 2,192 | $14K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 8,449 | $14K |
| 83970 | <1% | 876 | $14K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 4,264 | $14K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,515 | $14K |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 3,927 | $13K |
| 73090 | <1% | 740 | $13K | |
| 84550 | <1% | 2,803 | $13K | |
| 88307 | <1% | 395 | $13K | |
| 73080 | <1% | 734 | $13K | |
| 77080 | <1% | 285 | $13K | |
| 84479 | <1% | 1,766 | $12K | |
| 86900 | <1% | 3,366 | $12K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 2,121 | $12K |
| 82947 | <1% | 1,917 | $12K | |
| 84156 | <1% | 2,833 | $12K | |
| 85014 | <1% | 4,648 | $11K | |
| 71271 | <1% | 294 | $11K | |
| 86850 | <1% | 3,241 | $11K | |
| 71020 | <1% | 914 | $11K | |
| 84403 | <1% | 491 | $11K | |
| 72040 | <1% | 510 | $11K | |
| 93226 | <1% | 413 | $11K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 71 | $11K |
| 73521 | <1% | 532 | $11K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,195 | $11K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 205 | $10K |
| 96376 | <1% | 3,037 | $10K | |
| 85660 | <1% | 1,394 | $10K | |
| 74246 | <1% | 310 | $10K | |
| 84207 | <1% | 397 | $10K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 348 | $10K |
| 86336 | <1% | 461 | $10K | |
| 82784 | <1% | 1,762 | $10K | |
| 85652 | <1% | 3,749 | $9K | |
| 71010 | <1% | 1,400 | $9K | |
| 84425 | <1% | 502 | $9K | |
| 85018 | <1% | 3,907 | $9K | |
| 84132 | <1% | 2,796 | $9K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 4,215 | $8K |
| 77300 | <1% | 90 | $8K | |
| 96415 | <1% | 346 | $8K | |
| 72072 | <1% | 314 | $8K | |
| 75635 | <1% | 80 | $8K | |
| 78227 | <1% | 30 | $7K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 413 | $7K |
| 82378 | <1% | 551 | $7K | |
| 72050 | <1% | 306 | $7K | |
| 86003 | <1% | 251 | $6K | |
| 82140 | <1% | 1,135 | $6K | |
| 87522 | Neg quan hep c or qual rna | <1% | 228 | $6K |
| 82150 | <1% | 876 | $6K | |
| 97165 | <1% | 131 | $6K | |
| 72170 | <1% | 356 | $6K | |
| 93242 | <1% | 1,022 | $6K | |
| 83090 | <1% | 445 | $6K | |
| 29581 | <1% | 233 | $6K | |
| 84252 | <1% | 348 | $6K | |
| 83921 | <1% | 403 | $6K | |
| 80069 | <1% | 1,317 | $6K | |
| 82248 | <1% | 1,178 | $5K | |
| 85049 | <1% | 1,218 | $5K | |
| 85045 | <1% | 1,537 | $5K | |
| 87210 | <1% | 874 | $5K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 1,301 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,870 | $5K |
| 86920 | <1% | 264 | $5K | |
| 95912 | <1% | 70 | $4K | |
| 87045 | <1% | 412 | $4K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 241 | $4K |
| 84446 | <1% | 369 | $4K | |
| 82043 | <1% | 1,206 | $4K | |
| 97163 | <1% | 38 | $4K | |
| 97003 | <1% | 102 | $4K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 1,485 | $4K |
| 77412 | <1% | 89 | $4K | |
| 78264 | <1% | 90 | $4K | |
| 84100 | <1% | 1,253 | $4K | |
| 80055 | <1% | 105 | $4K | |
| 90715 | <1% | 238 | $4K | |
| 93923 | <1% | 139 | $4K | |
| 74000 | <1% | 264 | $4K | |
| 87902 | <1% | 17 | $4K | |
| Q3014 | Telehealth originating site facility fee | <1% | 1,522 | $4K |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | <1% | 124 | $3K |
| 72128 | <1% | 38 | $3K | |
| 12011 | <1% | 16 | $3K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 72 | $3K |
| 84590 | <1% | 365 | $3K | |
| A6196 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size 16 sq. in. or less, each dressing | <1% | 278 | $3K |
| 72158 | <1% | 12 | $3K | |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 272 | $3K |
| 86308 | <1% | 406 | $3K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,113 | $3K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 7,066 | $3K |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 469 | $3K |
| 87340 | <1% | 439 | $3K | |
| 97597 | <1% | 203 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 66 | $3K |
| 17000 | <1% | 144 | $3K | |
| 74230 | <1% | 90 | $3K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 889 | $3K |
| A6197 | Alginate or other fiber gelling dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 245 | $3K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,014 | $3K |
| 86376 | <1% | 172 | $3K | |
| 86480 | <1% | 54 | $3K | |
| 83001 | <1% | 105 | $2K | |
| 94729 | <1% | 124 | $2K | |
| 10060 | <1% | 12 | $2K | |
| 82172 | <1% | 256 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,306 | $2K |
| 82553 | <1% | 200 | $2K | |
| 84450 | <1% | 292 | $2K | |
| 95913 | <1% | 26 | $2K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 856 | $2K |
| 99152 | <1% | 1,435 | $2K | |
| 86431 | <1% | 384 | $2K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 12 | $2K |
| 64447 | <1% | 15 | $2K | |
| 94760 | <1% | 1,039 | $2K | |
| 74174 | <1% | 23 | $2K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 36 | $2K |
| 84460 | <1% | 242 | $2K | |
| 83013 | <1% | 60 | $2K | |
| 19083 | <1% | 14 | $2K | |
| 72020 | <1% | 103 | $2K | |
| 84591 | <1% | 381 | $2K | |
| 87046 | <1% | 531 | $2K | |
| 76870 | <1% | 61 | $2K | |
| A6022 | Collagen dressing, sterile, size more than 16 sq. in. but less than or equal to 48 sq. in., each | <1% | 64 | $2K |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | <1% | 58 | $2K |
| 11102 | <1% | 52 | $2K | |
| 93567 | <1% | 219 | $2K | |
| 73140 | <1% | 94 | $2K | |
| 72070 | <1% | 75 | $2K | |
| 96368 | <1% | 467 | $1K | |
| 80185 | <1% | 134 | $1K | |
| 82951 | <1% | 103 | $1K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,384 | $1K |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 676 | $1K |
| 82010 | <1% | 152 | $1K | |
| 86762 | <1% | 155 | $1K | |
| 84630 | <1% | 131 | $1K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,137 | $1K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 364 | $1K |
| 80143 | <1% | 139 | $1K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 175 | $1K |
| 82077 | <1% | 244 | $1K | |
| 87493 | <1% | 36 | $1K | |
| 97166 | <1% | 529 | $1K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,159 | $1K |
| A6257 | Transparent film, sterile, 16 sq. in. or less, each dressing | <1% | 832 | $1K |
| 82180 | <1% | 139 | $1K | |
| J1815 | Injection, insulin, per 5 units | <1% | 535 | $1K |
| 97602 | <1% | 49 | $1K | |
| 84445 | <1% | 15 | $1K | |
| 80179 | <1% | 118 | $1K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,332 | $1K |
| 86696 | <1% | 56 | $1K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,578 | $1K |
| 72081 | <1% | 40 | $1K | |
| J2704 | Injection, propofol, 10 mg | <1% | 3,816 | $989.69 |
| 82272 | <1% | 274 | $944.69 | |
| C1893 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, other than peel-away | <1% | 459 | $936.27 |
| 99153 | Mod sedat endo service >5yrs | <1% | 1,195 | $932.87 |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 1,920 | $909.18 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 6,609 | $892.64 |
| 73060 | <1% | 48 | $883.81 | |
| 84145 | <1% | 56 | $883.46 | |
| 86039 | <1% | 102 | $853.83 | |
| 82525 | <1% | 75 | $845.23 | |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | <1% | 178 | $818.77 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 17 | $789.73 |
| 92611 | <1% | 61 | $783.09 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 66 | $782.64 |
| 52000 | <1% | 16 | $759.56 | |
| 77072 | <1% | 26 | $731.43 | |
| 82247 | <1% | 134 | $731.34 | |
| C1874 | Stent, coated/covered, with delivery system | <1% | 15 | $730.80 |
| 85347 | <1% | 315 | $730.40 | |
| 93280 | <1% | 30 | $726.32 | |
| J9045 | Injection, carboplatin, 50 mg | <1% | 58 | $714.02 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,839 | $703.92 |
| 84481 | <1% | 50 | $703.07 | |
| 82785 | <1% | 35 | $697.47 | |
| 93312 | <1% | 33 | $692.35 | |
| 80178 | <1% | 62 | $689.90 | |
| 17311 | <1% | 19 | $677.91 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 3,947 | $658.11 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 151 | $657.00 |
| 83520 | <1% | 55 | $636.10 | |
| 74019 | <1% | 24 | $622.11 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | <1% | 32 | $621.13 |
| 84520 | <1% | 130 | $618.61 | |
| 83519 | <1% | 88 | $617.96 | |
| 84165 | <1% | 121 | $607.46 | |
| 86695 | <1% | 57 | $531.81 | |
| Q9956 | Injection, octafluoropropane microspheres, per ml | <1% | 1,843 | $527.03 |
| 86665 | <1% | 24 | $525.90 | |
| 97116 | <1% | 1,374 | $525.31 | |
| 86225 | <1% | 52 | $514.61 | |
| A6258 | Transparent film, sterile, more than 16 sq. in. but less than or equal to 48 sq. in., each dressing | <1% | 501 | $501.79 |
| 85384 | <1% | 73 | $500.61 | |
| J3490 | Unclassified drugs | <1% | 3,800 | $490.85 |
| 86694 | <1% | 36 | $489.28 | |
| 88185 | <1% | 16 | $471.87 | |
| C1760 | Closure device, vascular (implantable/insertable) | <1% | 20 | $470.00 |
| 82952 | <1% | 104 | $459.49 | |
| A4338 | Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each | <1% | 24 | $394.66 |
| 83721 | <1% | 82 | $381.42 | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 93 | $373.49 |
| 73564 | <1% | 18 | $370.07 | |
| 83002 | <1% | 14 | $367.75 | |
| 86235 | <1% | 66 | $349.68 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,182 | $346.50 |
| 90674 | <1% | 32 | $311.41 | |
| 91200 | <1% | 12 | $304.57 | |
| 96523 | <1% | 122 | $296.32 | |
| 82330 | <1% | 13 | $290.28 | |
| 81291 | <1% | 18 | $287.24 | |
| 83655 | <1% | 14 | $271.10 | |
| A6450 | Light compression bandage, elastic, knitted/woven, width greater than or equal to five inches, per yard | <1% | 43 | $270.57 |
| 82365 | <1% | 13 | $268.33 | |
| 82310 | <1% | 31 | $262.53 | |
| 95800 | <1% | 18 | $251.17 | |
| 90686 | <1% | 133 | $242.03 | |
| 86160 | <1% | 34 | $239.96 | |
| 81050 | <1% | 63 | $232.23 | |
| 86664 | <1% | 12 | $225.86 | |
| J2780 | Injection, ranitidine hydrochloride, 25 mg | <1% | 386 | $222.46 |
| 86663 | <1% | 12 | $201.22 | |
| 88184 | <1% | 16 | $194.51 | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 130 | $180.54 |
| 76882 | <1% | 19 | $180.00 | |
| 86705 | <1% | 15 | $179.87 | |
| 84295 | <1% | 55 | $174.38 | |
| 73552 | <1% | 15 | $169.44 | |
| 90658 | <1% | 16 | $168.84 | |
| 84480 | <1% | 17 | $162.00 | |
| 82652 | <1% | 12 | $157.48 | |
| 76376 | <1% | 14 | $140.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 300 | $139.51 |
| 96411 | <1% | 20 | $123.01 | |
| 87184 | <1% | 32 | $121.21 | |
| 83010 | <1% | 44 | $118.27 | |
| 89055 | <1% | 28 | $116.67 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 288 | $111.42 |
| 88313 | <1% | 18 | $105.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 18 | $87.69 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 60 | $85.53 |
| 0297T | <1% | 13 | $79.08 | |
| 88311 | <1% | 12 | $78.00 | |
| 0296T | <1% | 13 | $69.45 | |
| 90656 | <1% | 35 | $68.74 | |
| C9399 | Unclassified drugs or biologicals | <1% | 218 | $57.16 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 183 | $56.17 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 369 | $50.77 |
| 83521 | <1% | 38 | $48.84 | |
| G0008 | Administration of influenza virus vaccine | <1% | 225 | $46.78 |
| 82435 | <1% | 13 | $41.88 | |
| 36600 | <1% | 78 | $41.73 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 225 | $38.62 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 247 | $34.56 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 76 | $30.06 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 366 | $29.53 |
| 76000 | <1% | 226 | $25.73 | |
| C1758 | Catheter, ureteral | <1% | 171 | $24.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 292 | $19.78 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 91 | $3.95 |
| J1817 | Insulin for administration through dme (i.e., insulin pump) per 50 units | <1% | 613 | $0.60 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 874 | $0.38 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 397 | $0.11 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 32 | $0.10 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | <1% | 60 | $0.01 |
| 77012 | 0% | 48 | $0.00 | |
| 94667 | 0% | 16 | $0.00 | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 0% | 149 | $0.00 |
| 99215 | Doctor's office visit, returning patient (complex) | 0% | 14 | $0.00 |
| 90662 | 0% | 17 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 18 | $0.00 |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 0% | 44 | $0.00 |
| 36591 | 0% | 304 | $0.00 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 0% | 301 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 22 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 247 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 27 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 67 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 71 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBARBER, CHRIS (CEO)
Parent organizationST BERNARDS HEALTH CARE
| Provider | Location | Paid |
|---|---|---|
| ST Bernards Hospital INC. | Jonesboro, AR | $7.34M |
| ST Bernards Hospital INC | Jonesboro, AR | $3.26M |
| ST Bernards Hospital INC | Jonesboro, AR | $781K |
| ST Bernards Hospital, INC. | Jonesboro, AR | $166K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.